Cargando…
Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits
INTRODUCTION: Pyrotinib is a novel irreversible pan-HER tyrosine kinase inhibitor (TKI). However, real-world data of pyrotinib-containing therapy in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and developing brain metastases (BMs) are limited, and the geno...
Autores principales: | Wang, Hui, Liu, Qiaoyan, Zhang, Mi, Zhang, Juan, Ran, Ran, Ma, Yingying, Yang, Jiao, Wang, Fan, He, Shujuan, Zhao, Xiaoai, Wang, Le, Zhang, Lingxiao, Dong, Danfeng, Yang, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313114/ https://www.ncbi.nlm.nih.gov/pubmed/37397372 http://dx.doi.org/10.3389/fonc.2023.1105474 |
Ejemplares similares
-
Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study
por: Zhang, Lili, et al.
Publicado: (2021) -
Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
por: Ma, Xiaoping, et al.
Publicado: (2022) -
HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
por: Zhang, Xinyong, et al.
Publicado: (2020) -
The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
por: Wang, Xinwei, et al.
Publicado: (2022) -
Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
por: Chen, Qitong, et al.
Publicado: (2020)